EvaluatePharma - Boehringer Ingelheim - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Boehringer Ingelheim, the world's largest privately owned healthcare company focused on researching and developing, manufacturing & marketing pharmaceuticals that improve health & quality of life.
Listed or Private Company	Private
Company Classification	Global Majors
Company Website	Website

Full Company Profile Information

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Spiriva	tiotropium bromide	Anti-cholinergics	2,457²	3,042³	+24%
2	Micardis	telmisartan	Angiotensin II antagonists	1,540⁴	1,791⁵	+16%
3	Flomax/Alna	tamsulosin hydrochloride	Prostatic therapies	1,506⁶	1,580⁷	+5%

Note: Shaded Cells⁸

RX Sales Chart

Boehringer Ingelheim	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals⁹	11,756¹⁰	13,190¹¹	+12%

Therapy Area Focus in 2008

Boehringer Ingelheim
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	900
Cardiovascular	2,294
Central Nervous System	1,382
Gastro-Intestinal	844
Genito-Urinary	1,764
Musculoskeletal	404
Respiratory	5,140
Systemic Anti-Infectives	489
Other Rx & OTC Pharma	1,722

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Boehringer Ingelheim ¹²	230

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Event - Pradaxa adcom set for wide scrutiny (September 02, 2010)

ESC - Blood thinners generate strong data (August 31, 2010)

Preview - ESC likely to be dominated by oral blood thinners (August 26, 2010)

Preview - ESC to throw up more than just the hot topics (August 26, 2010)

Bayer’s Xarelto hot on the heels of Pradaxa (August 05, 2010)

Displaying 5 out of a possible 11 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXXX XX-XX:
XXXXX XXX XXXXXXX XXXXXX XX XXXX, XXXXXXX® XXX XXXX XXXX XXXXXXXXX XX XXXX XXXXXXXX XX XXXX XXXX XX XXXXXXXXX. XX XX XXX XXXX XXXXXXXXXX XXXXXXXXXX XXX XXXX XXX XX XXX XXXXX XXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXXX XXXX XXXXXX XXXXXXX®. XXXXXXXXXX XXX XXXXXXXXX XX XXXXXXXXXX XXXXXXXXX, XXXXXXX® XX XX-XXXXXXXX XXXXXXXXX XXXX XXXXXX XXX.

XXXXXXX® XXXXXXXXXX XXXXXXX
XXXXXXX®, XXX XXXX XXXX-XXXXX XXXX XXXXXXXXXX XXXX XXXXXXXXX XX-XXXX XXXXXXXXXXXXXXX XXXXXXX XXXXXXXXX XX XXXXXXXX XXXXXXXX, XXXXXXX XXXXXXXXXXXX XXXX XXX XXXXXXX XXX XXXXXX, XXXXXXXXX XX XXXXXXXXXXX XXX XXXXXXXXX XXXX-XXXX XXXXXXXXXXXX XX XXXX XXXXXXXX.
XXX XXXXX XXXX: XXX X,XXX XXXXXXX (+ XX.X %)

XXXXXXX® XX XXXXXXXXXXX XX XXXXXXXXXXXXX XXXXXXXXXX XX XXXXX-XXXX XXXXXXXXXXX XXXXXXX XXX XXXX. XX XXXXXXXXXX XXXXXXX XXX XXXXXXXX XXXXXX XX XXX XXXXXXX, XXXXXXX XX XXXXXX XXX XXX XXXXXXXX XXXX XXXX XXXXX XXXXXXXXX XXXX XXXX. XXX XXXXXXXX XXX XXXX XXXXXXXXXXXX XX XX XXXXXXXXX XXXXXXXX XXXXXXXXXXX XXXXXXXXX XXXXX XXXXXXXX XXXX XX,XXX XXXXXXXX.

XXXXXXX® XXXXXXXXXXX XXXXXXX XXX XXXX XXXXX XX XX XXXX XXXXXXXXX. XXX XXXX XXXXXXXXXX XXXXXXXX XXXXXXX XXXXXXXX XXXX XXXXXXX® XXX XXXX XXX XXXXX. XXXXX XX XXXX XXXX XXXXXXX XXXX XXXX XXX XXXXX XXXXXXXX XXXXXXXXXX XXXX XXXXXXXXX XXXXXXXXX.

XXX XXXXXXX® XXXXXXXX® XX X XXXXXX XXX XXXXXXXXXX, XXXXXXXXXX-XXXX XXXXXXX XXXX XXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXX XXX XXXXXX XXXXXXXX XX XXXXXXX®. XX XX XX XXXXXXXXX XXXXXXX XX XXXXXXXXXX XXXXXXX XXX XXXXXXXX XXXX XXXX. XXX XXXXXXX® XXXXXXXX® XXXX XXXX™ XXXXXXX, XXXX XXX XXXXXX XXXX-XXXXXX XXXX XXXX XXX XXX XXXX XXXX XXXXXXXX XXXXXXXX, XXXXXXXXX XXXX XXXXXXXX XXX XXXXXXXXXX XX XXXXXXXX’ XXXXX, XXXXXXXXX XX XXXXXXX XXXXXXXXXX XX XXX XXXXX XXX XXXXXX XXXXXXXX XXXX XXXXXXXXXXX XXXXX-XXXX XXXXXXXX.

XXX XXXXXXX® XXXXXXXX® XXXX XXXX™ XXXXXXX XXX XXXXXXXXXX XXXXXX XXXX XX XXXXXXX, XXX XXXXXX XXXXXXX, XXXXXXX XXX XXX XXXXXXXXXXX. XXXX XXXXXXXXX XXX XXXXXXXX XX XXXXXX XXXX XXXXXXXXXX XXXXXXX XX XXXX. XX XXXXXXXXXXXX XXXXXXXXX XXX XXXXXXXX XXXXXXXX XXXXX XXXXXXXXX XX XXXXXXX XX XXX XXXXXXXXXX XXX XXXXXXXXXXXX XX XXX XXXXXXX® XXXXXXXX® XXXX XXXX™ XXXXXXX XX XXXXX. XX XXX XXX, XXX XXXXXXX® XXXXXXXX® XXXX XXXX™ XXXXXXX XXX XXXX XXXXXXXXXXX (XXX) XXX XXXXX XX XXX XXXXXX XXXXXXX XXXX.

XXXXXXX XXXXXXX

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXX XXXXXXXXXX XXXX XXXXXXXXXX XXXXXXX® XXXXXXXXX XXX XXXXXXXXX XXXXX XX XX% XX XXX X,XXX XXXXXXX XX XXXX XXX XXXX XXXXXXXX XXXXX XX XXXX XXXX XXX X XXXXXXX XXX XXX XXXXX XXXX. XXXX XXXXX XXXX XX XX XXXX XXXXX XXX XXXXXXX XXXX XXX XXXXXXX XXXXX XX XXXXXXXXXX XXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXX®, XXX XXXX XXXXXXXXXX XXXX XXXXXXXX XXXXXXXXX, XXXXXXXXX XXX XXX XXXXX XX XXXXXXXX-XXXXXXXX +XX% XX €X.X XXXXXXX XXX XXXXXXXX XXX XXXXX XX XXXXXX XX €X XXXXXXX XXX XXX XXXXX XXXX. XX XXX XXXXXXX XXXX XXXXX XXXXXXXXXX XXXXXXXXX'X XXXX-XXXXXXX XXXXXXX.

XXXXXXXX XXXXXXX:
XXXXXXXXXX XXXXXXXXX XX XXXXXX XX XXXXX XXXX XXXX. XXXXXXXXXX XXXXXXXXX XXX XXXXXX XXXXXXXXXX XX-XXXXXXXX XX XXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXXX XX-XX:
XXXXXXXX®, XXX XX XXX XXXX XXXXXXXX XXXXXXXXXXXXXXXXX XX XXX XXXXXXXXXXX XXXXXXXX XXXXXXX (XXX) XXXXX, XX XXXX XXXXXXXXXXXXX XX XXX XXXXXXX XXXXXXXX XX XXXXXX XX XXX XXXXX XXX XX XXX XXXXXX XXXX XX XXX XXX-XX XXXXXXXX. XXXX X XXXX-XXXXX XXXXXX, X XXXXXXXX XXXXX XXXXXXXX XXXXXXX XXXX XXX XXXX XX-XXXX XXXXXX XX XXXXXXXX. XXX XX XXX XX-XXXX XXXXXXXX, XX XX XXX XXXX XXX XXX XXXXXXXX XXX XXXXX XXXXX XXXXXXX XXXXX XXXXXXXX XXXXXXXX.

XXX XXXXXXXX XXXXXXX XX XXXXXXXXXXXXXX XXXXXXXXXX XXX XXXXXXXXXXXX

XXXXXX XXX XXXXXXXXX XX XXXXXXXXXXXX, XXXXXXXX® XXXXX, XX XX XXXXXXXXXXX XXXX XXXXXXXX, XXX XXXXXXXX XXXXXX XXXXXXXX™ XXX XXXXXXXXX® XXX XXXXXXXXXXXXX XXXXXXX XXXXXXXXXX XX XXXXXXXXXXXXXX XXXXXX, XXXX XX XXXXX XXXXXXXXXX XXXXXXXXXX, XXXXXX XXX XXXXX XXXXXXX, XX XXXXXXXXXX. XXX XX XXX XXXXXXXXXXX XXXXXXXXXX XX XXXXXXXX® XXX XXX XXXXXXXXXXXXX XXXXXX XXXX XXXXXXXX, XX XX XXXXXXXX XXXX XXX XXXXXXX XX XXXXXXXX™ XXXX XXXX X XXXXXXXX XXXXXX XX XXX XXXXX XX XXXXXXXXXXXXXX XXXX-XXXX XXXXXXXX.

XXX XXXXXXXX® XXXXXXXX XXXXXX XXXXXXXX™ XXX XXXXXXXXX® XXXX XXXXXXX XXXXX XXXXX-XXX XXXXX XX XXXXXXXXXXX XXXX XXX XXXXXXXX XXXXXXXX XXXXXXXX XXXXXXX XXXX XXXXX XX XXXX XXXXXXXXX XXX XXXXXXXXX. XXXX XXXX XX XXXX XXXX XX,XXX XXXXXXXX, XXXXXXXX XXX XXX XXXXX XXXXXXXXX XX XXXX XXXXXXX XXXXXXX XXXXXXXXX XX XXX XXXXXX XX XXX XXXXX XXXX XX XXXX.

XXX XXXX-XXXXXXXXXXX XXXXXXXXXXXXXXXX XXXXXXXX XX XXXXXXXX® XXX XXXXXXXXX XX XXXXXXXXXXX XXXXXXXX XXXXXXX XXXXXXXXXXXXX XXXXXXXX® XXXXX XXX XX XXXXXXXXXXX XXXX XXXXXXXXXX, XXXXXXXX XXX XXX XXXXX-XXXXXXXX XXXXXX XXXXXXXXXXX. XXXXXX-XX XXXXXX XXXX XXXXXXXXXXX XXX XXXXXXXX XX XXXXXXXX® XX XXXXXXXXXXXX XXXXXXXX XXX, XX XXX XXXXXXXXXXXX, XXXXXXXXXX XX XXXXXXXXXX XXXXX.

XXXXXXXX XXXXXXX:
XXXXXXXXXX XXXXXXXXX XX XXXXXX XX XXXXX XXXX XXXX. XXXXXXXXXX XXXXXXXXX XXX XXXXXX XXXXXXXXXX XX-XXXXXXXX XX XXX.

XXXXXXX XXXXXXX

XXXXXX: XXXX XXXXXX XXXXXX, XXXX X:
XXX XXXXXXXXXXX XXXXXXXX XXXX XXXX XXX XXXXX XX XXXX XXXX XXX X XXXXXXX, XXXXXXXX®...
...XXXXXXXXX XX XXXXXXX XXXXXX XX XXXX XXXX XX % XXXXXXXX XX XXX XXXXXXXX XXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXXX®, XXX XXXXXXXXXXXX XXXXXXXX, XXXXXXXX XXX XXXXX XX €X.X XXXXXXX XXX XXXXXXXX-XXXXXXXX XXXXXX XX +XX%.

XXXXXXXX XX €X:
X) +XXXX XXXXXX, XXXX, XXXXX, XXXXXX, XXXXXXX & XXXXXXXX XXXXX.
X) +XX XXXXXX XXXX XXXXX.

XXXXXXXX XXXXXXX:
XXXXXXXXXX XXXXXXXXX XX XXXXXX XX XXXXX XXXX XXXX. XXXXXXXXXX XXXXXXXXX XXX XXXXXX XXXXXXXXXX XX-XXXXXXXX XX XXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXXX XX-XX:
XXXXXXXXXX XXXXXXXXX XXXXXX XXX XXXX-XXXXXXXXXXX XXXXX-X XXXXXXXX XXXXXXXXXX XXXXXXXXXX (XXXXXX®, XXXX®, XXXXXX® XXXX®) XX XXXXX XXXXXX XXXXXXXX XXXXXXXXXXX.
XXXXXX XXXXXXXX XXXXXXXXXXX
XXXXX XXXXXXX XXXXX XXXXXXXX (XXXX) XXXXXXXXXX XX XXXXXX XXXXXXXX XXXXXXXXXXX (XXX) XXX XXXXX XXX XXXX XXXXXX XXXXXXXXXX XXXXXXXXX XX XXXXX XXX. XXXX XXXXXXX XXXXXXX XX XXXXXXXXXXXXX XX XXX XXXXXXXX XX XXXXXXX XXXXXXX XXXXXXXX XXXX XXX XX XXXXXXX XX XXXXXXX XXXXXXXX (XXXXXXX XX XXXXXXXXXXX XXXXXXXX) XX XXXXXXX (XXXXXXX XX XXXXXXXXXX XXXXXXXX).

XXXXXXX XXXXXXX XXXXXXXX XXX XXXX XXXXXX, XXXXXXXXX XXX XXXXXXXXXXXXX. XXXXXXX XXXXXXX XXXXXXXX XXX XXXXXXXXX XXXXXXX XXXXXXXXX, XXXXXXXX XXX XXXXXXX. XXXXXXXX, X. X. XXXXXXXXX XXX XX XXXX XXXXX XX XXXXX XXX XXXXXXX, XXXXXXX XXX XXXXXXX’X XXXXXXX XX XXXXX XXX XXX X XXXXXXXXXXX XXXXXXXX XXXXXX XX XXX XXX XXXXXXX XXXXX XXX XXXX XXX XX XXXXX XX XXXXXX XXXXX/XXXXXXX, XXXXXXXXXXXXX XXX XXXX XXX XXXXXXXXXX XXXXXXX XXXX-XXXXX XXX XXXXXXX XX XXXX.

XXXXXXXXXXXXXXX XXXXXXX, XX XXXXXXXXXX XXXXX-X XXXXXXXX XXXXXXXXXXX, XX XXX XXXXXXXXXXX XX XXXXXXX XXXXXXXXX XXX XXXX XXXXXXXXX, XX XXXXXXX XXXXXXXXXX XXXXXXXX, XX XXXXXX XXX XXXXXX XXX/XX XXXXXXX XXXXXXXXX XX XXXXXXXXXXX XXX XX XXXXXXX XXX XXXXXXX XX XXXX.

XXXXXX® XXXX® XXXXX® XXXXXX® XXXXXXX® XXXXXXXX® XXXXXXXXXX
XXXXXX®/XXXX® XXXXXXXX, XX XXXXX-X XXXXXXXX XXXXXXXXXX, XXX XXXXXXXXX XXX XXX XXXXXXXXX XX XXXXX XXXXXXX XXXXX XXXXXXXX (XXXX) XXXXXXXXXX XX XXX XXX XXXXXXX XXXXXXXXX XXX XXXX XXXXXXXXXXX XX XXXXXXXX.
XXX XXXXX XXXX: XXX X,XXX XXXXXXX (+ XX.X %)

XXXXXX® XXXX® XXXXXXXXXX
XXXXXX® XXXX®, X XXX XXXXXX XXXXXXXXXXX, XXXXX XXX XXXX XXXXXXXXXX XXXXXXXXXX XXXXXX (XXXX®), XXX XXXXXXXXX XX XXXXXXXXXX XXXXXXXXX XXX XXX XXXXXXX
XXXXXXXX XX XXXXXXX XXXXXXXX XXXXXXXXXXXXXXX XXXXXXX XXX XXXX/XXX.
XXX XXXXX XXXX: XXX XX XXXXXXX (+ XX.X %)
XXX XXXXXX® XXXX® XXXXXX XXXXXXXX XXXXXXXXX XXXXXXX XXX XXXXXXXXX XXXXXXX XXXXXXX, X XXXX XXXX XXXXXX XXXXXXX XXX XXXXXXXXX XXXXXXXXXXX XXX XXX XXXXXXX (X. X. XXXX-XXXXX XXXXXX XXXXXXX XXX XXXX XX XXXX XXXXXXXXX XXX XXXXXXXXXX XXXXXX XXXXXXXXXXX XX XXXXX).

XXXXXX®/XXXX® XXXXX XXX XXXX® XXXXXXXXXX, XXXXXXX XXXXXXXXX XX XXXXXXX, XXXXX, XXXXXXXXXXX, XXXXXXXX, XXXXXX, XXXXXX XXX XXXXXX, XXX XXXXXXXX XX XXXXXXXXX XXX XXXXXX XX XXXX.

XXX XXXXXXXX XXXXXXX XX XXXXXXX
XXXXXX®, XXX XXXXXXX XXXXXXXXX XXX XXX XXXXXXXX XX XXX, XX XXXXXXXXXXX XXXXXXXXX XX XXX XXXXXXXXX XX XXXXXXXX XXXX XXXXXXXXXX XXXXXXX XXXXXXXXXXX. XXXXXXXX XXXXXXXX XXX XXXXX XXXXX XXXXXXXXX XXX XXXXXXXXXX XXXXXXXXXXXX XXXXX XXXXXX. XX XXXXXXXXX XXXX XXX XX XXXX XXX XXXX XXXXXXXXXXXXXX (XXX) XX XXXX X XXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXX.

XXXXXXXX XXXXXXX:
XXXXXXXXXX XXXXXXXXX XX XXXXXX XX XXXXX XXXX XXXX. XXXXXXXXXX XXXXXXXXX XXX XXXXXX XXXXXXXXXX XX-XXXXXXXX XX XXX.

XXXXXXX XXXXXXX

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XXXX XXXXXX®, XXXX XX XXX XXXXXXXXX XX XXXXXX XXXXXXXXX XXXXXXXXXXX (XXX), XXXXX XXXXXXXXX XX X%.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX®/XXXX®, XXX XXX XXXXXXXXX XX XXX XXXXXXXX XX XXXXXX XXXXXXXX XXXXXXXXXXX, XXXXXXXXX XXX XXXXX XXXXXXXXX XX €X.X XXXXXXX XXX XXXXXXXX XXXXXXXX-XXXXXXXX XXXXXX XX +XX%.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NamePrescription Medicines (excluding sales booked by Abbott)

XXXXXXXX XX €X:
X) +XXXX XXXXXXXXXXXX XXXXXXXXX.
XXXXX
X) +XX XXXXXXXX/XXXXXXXX (XXXXXXXXXX) XX-XXXXXXXXX XXXXXXX XXXX XXX XXXXX.

XXXXXXXX XX €X:
X) +XXXX XXXXXXXXXXXX XXXXXXXXX.
XXXXX
X) +XXX.XXX XXXXXXXX/XXXXXXXX (XXXXXXXXXX) XX-XXXXXXXXX XXXXXXX XXXX XXX XXXXX.